prikaz prve stranice dokumenta Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
  Download
PDF 723.44 KB
Scientific paper - Original scientific paper
Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
Clinical Genitourinary Cancer, 20 (2022), 5; e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001
Makrakis, Dimitrios; Talukder, Rafee; Lin, Genevieve Ihsiu; Diamantopoulos, Leonidas N.; Dawsey, Scott; Gupta, Shilpa; Carril-Ajuria, Lucia; Castellano, Daniel; de Kouchkovsky, Ivan; Koshkin, Vadim S.; Park, Joseph J.; Alva, Ajjai; Bilen, Mehmet A.; Stewart, Tyler F.; McKay, Rana R.; Tripathi, Nishita; Agarwal, Neeraj; Vather-Wu, Naomi; Zakharia, Yousef; Morales-Barrera, Rafael; Devitt, Michael E.; Cortellini, Alessio; Fulgenzi, Claudia Angela Maria; Pinato, David J.; Nelson, Ariel; Hoimes, Christopher J.; Gupta, Kavita; Gartrell, Benjamin A.; Sankin, Alex; Tripathi, Abhishek; Zakopoulou, Roubini; Bamias, Aristotelis; Murgic, Jure; Fröbe, Ana; Rodriguez-Vida, Alejo; Drakaki, Alexandra; Liu, Sandy; Lu, Eric; Kumar, Vivek; Lorenzo, Giuseppe Di; Joshi, Monika; Isaacsson-Velho, Pedro; Buznego, Lucia Alonso; Duran, Ignacio; Moses, Marcus; Jang, Albert; Barata, Pedro; Sonpavde, Guru; Yu, Evan Y.; Montgomery, Robert Bruce; Grivas, Petros; Khaki, Ali Raza More authors...

Institutional repository: University of Zagreb School of Dental Medicine Repository

Cite this document

Makrakis, D., Talukder, R., Lin, G. I., Diamantopoulos, L. N., Dawsey, S., Gupta, S. ... Khaki, A. R. (2022). Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer, 20. (5), e440-e452. doi: 10.1016/j.clgc.2022.06.001

Makrakis, Dimitrios, et al. "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clinical Genitourinary Cancer, vol. 20, no. 5, 2022, pp. e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

Makrakis, Dimitrios, Rafee Talukder, Genevieve Ihsiu Lin, Leonidas N. Diamantopoulos, Scott Dawsey, Shilpa Gupta, Lucia Carril Ajuria, et al. "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma." Clinical Genitourinary Cancer 20, no. 5 (2022): e440-e452. https://doi.org/10.1016/j.clgc.2022.06.001

Makrakis, D., et al. (2022) 'Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma', Clinical Genitourinary Cancer, 20(5), pp. e440-e452. doi: 10.1016/j.clgc.2022.06.001

Makrakis D, Talukder R, Lin GI, Diamantopoulos LN, Dawsey S, Gupta S, and sur.. Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. Clinical Genitourinary Cancer [Internet]. 2022 October [cited 2025 January 17];20(5):e440-e452. doi: 10.1016/j.clgc.2022.06.001

D. Makrakis, et al., "Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma", Clinical Genitourinary Cancer, vol. 20, no. 5, pp. e440-e452, October 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:127:400491. [Accessed: 17 January 2025]

Metadata
Title (english)Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
AuthorDimitrios Makrakis
AuthorRafee Talukder
AuthorGenevieve Ihsiu Lin
AuthorLeonidas N. Diamantopoulos
AuthorScott Dawsey
AuthorShilpa Gupta
AuthorLucia Carril-Ajuria
AuthorDaniel Castellano
AuthorIvan de Kouchkovsky
AuthorVadim S. Koshkin
AuthorJoseph J. Park
AuthorAjjai Alva
AuthorMehmet A. Bilen
AuthorTyler F. Stewart
AuthorRana R. McKay
AuthorNishita Tripathi
AuthorNeeraj Agarwal
AuthorNaomi Vather-Wu
AuthorYousef Zakharia
AuthorRafael Morales-Barrera
AuthorMichael E. Devitt
AuthorAlessio Cortellini
AuthorClaudia Angela Maria Fulgenzi
AuthorDavid J. Pinato
AuthorAriel Nelson
AuthorChristopher J. Hoimes
AuthorKavita Gupta
AuthorBenjamin A. Gartrell
AuthorAlex Sankin
AuthorAbhishek Tripathi
AuthorRoubini Zakopoulou
AuthorAristotelis Bamias
AuthorJure Murgic
AuthorAna Fröbe
AuthorAlejo Rodriguez-Vida
AuthorAlexandra Drakaki
AuthorSandy Liu
AuthorEric Lu
AuthorVivek Kumar
AuthorGiuseppe Di Lorenzo
AuthorMonika Joshi
AuthorPedro Isaacsson-Velho
AuthorLucia Alonso Buznego
AuthorIgnacio Duran
AuthorMarcus Moses
AuthorAlbert Jang
AuthorPedro Barata
AuthorGuru Sonpavde
AuthorEvan Y. Yu
AuthorRobert Bruce Montgomery
AuthorPetros Grivas
AuthorAli Raza Khaki
Author's institution(Sestre milosrdnice University Hospital Center)
Author's institutionUniversity of Zagreb
School of Dental Medicine
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Abstract (english)
Background: Sites of metastasis have prognostic significance in advanced urothelial carcinoma (aUC), but more information is needed regarding outcomes based on metastatic sites in patients treated with immune checkpoint inhibitors (ICI). We hypothesized that presence of liver/bone metastases would be associated with worse outcomes with ICI. Methods: We identified a retrospective cohort of patients with aUC across 26 institutions, collecting demographics, clinicopathological, treatment, and outcomes information. Outcomes were compared with logistic (observed response rate; ORR) and Cox (progression-free survival; PFS, overall survival; OS) regression between patients with/without metastasis beyond lymph nodes (LN) and those with/without bone/liver/lung metastasis. Analysis was stratified by 1st or 2nd+ line. Results: We identified 917 ICI-treated patients: in the 1st line, bone/liver metastases were associated with shorter PFS (HR: 1.65 and 2.54), OS (HR: 1.60 and 2.35, respectively) and lower ORR (OR: 0.48 and 0.31). In the 2nd+ line, bone/liver metastases were associated with shorter PFS (HR: 1.71 and 1.62), OS (HR: 1.76 and 1.56) and, for bone-only metastases, lower ORR (OR: 0.29). In the 1st line, LN-confined metastasis was associated with longer PFS (HR: 0.53), OS (HR:0.49) and higher ORR (OR: 2.97). In the 2 nd+ line, LN-confined metastasis was associated with longer PFS (HR: 0.47), OS (HR: 0.54), and higher ORR (OR: 2.79); all associations were significant. Conclusion: Bone and/or liver metastases were associated with worse, while LN-confined metastases were associated with better outcomes in patients with aUC receiving ICI. These findings in a large population treated outside clinical trials corroborate data from trial subset analyses.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleClinical Genitourinary Cancer
Numberingvol. 20, no. 5, pp. e440-e452
p-ISSN1558-7673
DOIhttps://doi.org/10.1016/j.clgc.2022.06.001
URN:NBNurn:nbn:hr:127:400491
Publication2022-10
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S1558767322001252
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2024-10-22 07:12:48